Drug Trial Radar · NCT02503423
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
253
Actual
Start
Jul 14, 2015
Primary completion
Oct 2022
Study completion Dec 2027
Sponsor
- Lead sponsor
- Taiho Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.
Conditions
- Solid Tumors
- Lymphoma
Interventions
ASTX660Drug
described above
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (Phase 1) - number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam resultsTime frame: Up to 78 months
- Efficacy (Phase 2) - antitumor activity assessed by objective response rate (ORR)Time frame: Up to 84 months
- Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR)Time frame: Up to 84 months
Locations
68 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
HonorHealth Research Institute
Scottsdale, Arizona
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
Simlow Cancer Hospital at Yale
New Haven, Connecticut
Emory University winship Cancer Institute
Atlanta, Georgia
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Dartmouth-Hitchcock Medical Center (DHMC)
Lebanon, New Hampshire
Summit Medical Group - Florham Park Campus/Atlantic Health
Florham Park, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
New York University Langone Medical Center
New York, New York
New York Presbyterian Hospital Columbia University Medical Center
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Rochester Skin Lymphoma Medical Group
Rochester, New York
Wake Forest Baptist Health
Winston-Salem, North Carolina
The Ohio State University and Wexner Medical Center, James Cancer Hospital
Columbus, Ohio
University of Oklahoma Stephenson Cancer Center
Oklahoma City, Oklahoma
Oregon Health and Science University
Portland, Oregon
West Penn Hospital
Pittsburgh, Pennsylvania
Hollings Cancer Center
Charleston, South Carolina
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
CliniCore Texas
Houston, Texas
START- South Texas Accelerated Research Therapeutics
San Antonio, Texas
Virgina Commonwealth University
Richmond, Virginia
University of Washington, Seattle Cancer Care Alliance
Seattle, Washington
Intitut Jules Boredt
Brussels, Belgium
Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne
Yvoir, Namur, Belgium
Universitair Ziekenhuis Gent
Ghent, Oost-Vlaanderen, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
Nova Scotia Health Athority-Qeii HSC
Halifax, Nova Scotia, Canada
Sunnybrook Hospital
Toronto, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.